| Autor: |
Sutton, Shawn Scott, Gomez-Fein, Eleanor, Papadopoulos, John, Olyaei, Ali, Cazes, John, Hennenfent, Joel, Ambegaonkar, Ambarish J., Lubowski, Teresa J. |
| Zdroj: |
Hospital Pharmacy; March 2003, Vol. 38 Issue: 3 p232-240, 9p |
| Abstrakt: |
Purpose To evaluate the use of lipid amphotericin B products in relation to risk factors for aspergillosis and candidemia at the time therapy was initiated.Methods A single-group, concurrent, observational, multicenter study in hospitalized patients receiving a lipid amphotericin B product (Abelcet or AmBisome) was undertaken. The severity of illness, duration of therapy, length of hospital stay, microbiology, all-cause mortality, physician specialty, and clinical characteristics of each patient was recorded. Risk factors for aspergillosis and candidemia and process markers that might identify patients as candidates for lipid amphotericin B therapy were collected.Results One hundred eighty-six patients were enrolled in six US medical centers. One hundred four patients had positive fungal cultures; the majority of positive cultures were for Candida albicans (n = 40) or yeast (n = 27). Sixteen patients had positive cultures for Aspergillus. All patients receiving a lipid amphotericin B product had an overall statistically significantly greater number of risk factors for Candida vs Aspergillus infection. The mean (± SD) number of risk factors for Aspergillus was 2.46 ± 1.97 (range 0–10) and for Candida was 7.77 ± 3.14 (range 1–16) (P < 0.05). Risk factor assessment by medical service showed a statistically significantly larger number of Aspergillus risk factors in the bone marrow transplant (BMT) service compared with all other services (P < 0.05).Conclusions There were fewer documented risk factors for aspergillosis than candidemia in patients receiving a lipid amphotericin B product. Establishing drug usage protocols that include culture analysis, risk factor identification, high-risk medical services, and incorporation of drug use evaluation measures can guide the practitioner in selecting the appropriate therapy for their patients. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
